HEALTH PLANS AND CONSUMERS SETTLE ANTITRUST CASE WITH MAKERS OF DDVAP

SRKW is pleased to announce that the class of end-payors (mainly consumers and health plans) who purchased DDAVP (a prescription anti-diuretic medicine) has settled its generic suppression claims against Fering and Aventis Pharmaceuticals. Complete details of the settlement, and claim forms, can be found at the settlement website: www.ddavpsettlement.com

SRKW serves as co-lead counsel in this litigation, which has survived an appeal to the Second Circuit and the death of the original trial judge. Shortly after a favorable ruling against the defendants’ Motion to Dismiss the case, the plaintiffs reached settlements totaling $4.75 million. The plaintiffs’ claims related to overpayments by consumers and health plans over several years, caused by Fering and Aventis’ actions to keep generic versions of DDAVP off the market. SRKW partner Jeffrey Kodroff said, “We are pleased to resolve yet another case where a brand name drug company suppressed generic competition. We will continue working for consumers and health plans to insure that generic drugs are as widely available as possible.”